(ü 195) |
|
|
|
|
[] ƽƮī, '簢 濪'
ƽƮī ǰǾǰó ϰ ѱ̿Ǿǰȸ ְϴ '2022 ۷ι ̿ ۷(Global Bio Conference 2022, 2022 GBC)' ߴ. ䷹(John P
ϼ
2022-09-06
|
|
|
|
|
[] ѱũ ̿ĸ, ް ̷ ķ
ũ Ǿǰ ѱũ ̿ĸ Ƶ ް ϱ ķΡ 8 ϰ, Ⱓ ݵ üȰ , ũ Ժ ʷϿ ܿ ߴٰ .
ϼ
2022-09-06
|
|
|
|
|
[] GC-ڸ FDA ȯ߽ žళߡ ȸ
GCڰ Ʈʻ ̱ ̿ (Speragen) Բ ̱ ǰǾ౹(FDA) ϴ 'ܺ ֵ ȯ (EL-PFDD, Externally-Led Patient-Focused Drug Development
ϼ
2022-08-31
|
|
|
|
|
[] " ѱ ð Ƿ , 롱
Ƿ ð ۷ι Ź Į ڸƴ 16, ۷ι ̳ ī(Rainer Burkard) ǥ Ͽ ð ֿ ذڵ ٰ 25 .̹ ۷ι 濵
ϼ
2022-08-25
|
|
|
|
|
[] ھƮ֡
۷ι コɾ ѱ ¾ 10 ڻ ھƮ(Vaxigrip Tetra) ߴٰ .Ǵ 2022-2023 ʿ
2022-08-16
|
|
|
|
|
[] ѱɴ, õ ܹC ġ ƾ֡ 㰡
ѱɴ(ǥ ) õ ܹC ġ ƾ(ܹC) 2 ǰǾǰóκ 㰡 Ҵٰ . õ ܹC ŸK ܹC
ϼ
2022-08-03
|
|
|
|
|
[] Ǿ̿, ȯ ġ Ը
-̰(Cyro-EM) ü ܹ(Glyco-protein) - ž Ⱓ ȹ ɼ Բ ž ü ̷
ϼ
2022-07-12
|
|
|
|
|
[] GCǷ, 24ȸ ӻȭȸ(IFCC)
GC 3 迭 GCǷ ÷Ƽ 24ȸ ӻȭȸ(IFCC Seoul 2022) Ȳ ߴٰ 8 .GCǷܰ GCMS, GC, GC ̹ ȸ
ϼ
2022-07-08
|
|
|
|
|
[] ѱƼ, ġ ľó 㰡 ȹ
ѱƼ(ǥ ) ġ (и: ֽù̴) ǰǾǰóκ 2 ̻ Ƽν Ű (Tyrosine kinase inhibitor, TKI) ġḦ ʶǾ ü 缺
ϼ
2022-06-28
|
|
|
|
|
[] ö , ۷ι コɾ ֿ λ
۷ι コɾ Ǵ Ż ֿ λ Ͽ ö 20 μȸ ( ǿ) 24 ٰ . 11ú 1ð ǿ R&D ι Ѱϰ
ϼ
2022-06-27
|
|
|
|
|
[] ڷγ19 'īں' ӹ...̹
ڷγ19 SK̿̾ 'īں'(GBP510) Ǵ籹 㰡 ΰ ̹ ȿ ǰ ̴.26 ࡤ̿ 迡 ǰǾǰó SK̿̾ īں ǰ㰡
ϼ
2022-06-26
|
|
|
|
|
[] GC, ȸ õ
캴 ġ ü GC(ǥ ö) 20 翡 縦 ߴٰ 21 . ̹ 縦 âȭ 4 ƴ.GC
ϼ
2022-06-21
|
|
|
|
|
[] 뺸 ũ, Talk2Grow
ѱ 뺸 ũ(: ) 6 10~11, ڹ輭 £ ҾƳк Talk2Grow Ȳ ƴٰ 20 . • ̺긮
ϼ
2022-06-20
|
|
|
|
|
[] ѱɴ, ̼ Ŵ
- Ѱ, ̽þ ̰ - ɴ, α źźϰ ѱɴ(ǥ ) (Oncology BU) Ѱ ̼ Ŵ
ϼ
2022-06-20
|
|
|
|
|
[] GC, ȯ溸ȣ õ ȸ ķ
캴 ü GC(ǥ ö) ֱ 迭 Բ ȯ ȣ õ ķ Reaction ߴٰ 9 . Reaction ķ ȯ ȣϱ 츮 ൿڴ ȹƴ.̹ ķ ȯ
ϼ
2022-06-09
|
|
|
|
|
[] ѱɴ, ȯ ¾ ݷ 200
ѱɴ(ǥ ) ȣ NGO ð Բ 6 5 ȯ Ͽ 6 ް ݷ ĸ ϴ ȸåȰ(CSR) ģٰ .ѱɴ
2022-06-08
|
|
|
|
|
[] JW߿, 2022 ̿ USA
JW߿ ̴ 13(ð) 갣 ̱ ̰ 2022 ̿ ͳų ( ̿ USA) ؿ 11 ȸ Ѵٰ 7 .JW߿ ̹ 翡
2022-06-07
|
|
|
|
|
[] Ž, 2022 ƽþƮֽ̾ Ʈ èǾ
Ž 4Ϻ 5ϱ ֵ 2022 ƽþƮֽ̾ Ʈ èǾ ߴٰ .ȣ ϴ뿡 ̹ ȸ ƽþ ְ ö3ȸ, ƽþƮֽ̾п(ASTC) 36 ȸ
2022-06-07
|
|
|
|
|
[] GC, ķ ǽ
캴 ġ ü GCڰ ϰ ȭ ӵ ̰ ִ.GC(ǥ ö) ∙ع ؼϴ ȭ Ȱ ķ
ϼ
2022-06-03
|
|
|
|
|